U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C35H41N5O5
Molecular Weight 611.7305
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIHYDROERGOCRISTINE

SMILES

[H][C@@]12CCCN1C(=O)[C@H](CC3=CC=CC=C3)N4C(=O)[C@](NC(=O)[C@H]5CN(C)[C@]6([H])CC7=CNC8=C7C(=CC=C8)[C@@]6([H])C5)(O[C@@]24O)C(C)C

InChI

InChIKey=DEQITUUQPICUMR-HJPBWRTMSA-N
InChI=1S/C35H41N5O5/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34/h4-7,9-12,18,20,23,25,27-29,36,44H,8,13-17,19H2,1-3H3,(H,37,41)/t23-,25-,27-,28+,29+,34-,35+/m1/s1

HIDE SMILES / InChI

Molecular Formula C35H41N5O5
Molecular Weight 611.7305
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Dihydroergocristine is an ergot alkaloid that has an partial agonist activity on dopaminergic and alpha-adrenergic receptors and antagonist activity on serotonin receptors. The drug was approved by FDA in combination with other alkaloids (dihydroergocornine, dihydro-alpha-ergocryptine and dihydro-beta-ergocryptine mesylate salts) under the name Hydergine for the treatment of dimentia and cerebrovascular insufficiency.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
HYDERGINE

Approved Use

The treatment of senility and cerebrovascular insufficiency.

Launch Date

2.52288008E11
Primary
HYDERGINE

Approved Use

The treatment of senility and cerebrovascular insufficiency.

Launch Date

2.52288008E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.28 μg/L
18 mg single, oral
dose: 18 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIHYDROERGOCRISTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.63 μg/L
18 mg single, oral
dose: 18 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
8'-HYDROXY-DIHYDROERGOCRISTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.46 μg × h/L
18 mg single, oral
dose: 18 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIHYDROERGOCRISTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
13.36 μg × h/L
18 mg single, oral
dose: 18 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
8'-HYDROXY-DIHYDROERGOCRISTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.5 h
18 mg single, oral
dose: 18 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIHYDROERGOCRISTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
3.9 h
18 mg single, oral
dose: 18 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
8'-HYDROXY-DIHYDROERGOCRISTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg 1 times / day steady, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 55 - 80 years
n = 20
Health Status: unhealthy
Condition: chronic cerebro-vascular disease
Age Group: 55 - 80 years
Sex: M+F
Population Size: 20
Sources:
Other AEs: Gastric pain...
Other AEs:
Gastric pain (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Gastric pain 1 patient
20 mg 1 times / day steady, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 55 - 80 years
n = 20
Health Status: unhealthy
Condition: chronic cerebro-vascular disease
Age Group: 55 - 80 years
Sex: M+F
Population Size: 20
Sources:
PubMed

PubMed

TitleDatePubMed
Effects of phentolamine, dihydroergocristine and isoxsuprine on the blood pressure and heart rate in normotensive, hypotensive and hypertensive rats.
1975
Patents

Sample Use Guides

The recommended dosage (in form of hydergine tablets containing dihydroergocornine, dihydroergocristine, dihydro-alpha-ergocryptine and dihydro-beta-ergocryptine mesylate salts in an approximate weight ratio of 1:1:1) in the US is 1 mg three times daily. In Europe and Japan, up to 12 mg of hydergine daily have been used without serious adverse effects.
Route of Administration: Oral
In Vitro Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/6438125
C-1300 neuroblastoma cells were incubated with dihydroergocristine at concentration of 2 uM. In another experiment dihydroergocristine was added to the perfusion medium of the isolated rat brain in a concentration of 5 uM. In both experiments the drug caused changes in the concentrations of the high-energy phosphates.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:43:16 UTC 2023
Edited
by admin
on Fri Dec 15 15:43:16 UTC 2023
Record UNII
05D48LUM4Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIHYDROERGOCRISTINE
VANDF   WHO-DD  
Common Name English
Dihydroergocristine [WHO-DD]
Common Name English
GNF-PF-3462
Code English
DIHYDROERGOCRISTINE [VANDF]
Common Name English
EROTAMAN-3',6',18-TRIONE, 9,10-DIHYDRO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(PHENYLMETHYL)-, (5'ALPHA,10ALPHA)-
Common Name English
9,10-DIHYDROERGOCRISTINE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66884
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
WHO-ATC C04AE04
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
WHO-VATC QC04AE04
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
WHO-VATC QC04AE54
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
WHO-ATC C04AE54
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
NCI_THESAURUS C29713
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
Code System Code Type Description
DRUG CENTRAL
887
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
PRIMARY
CAS
17479-19-5
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
PRIMARY
CHEBI
59912
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
PRIMARY
ChEMBL
CHEMBL601773
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
PRIMARY
PUBCHEM
107715
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
PRIMARY
DAILYMED
05D48LUM4Z
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
PRIMARY
WIKIPEDIA
Dihydroergocristine
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
PRIMARY
DRUG BANK
DB13345
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
PRIMARY
EVMPD
SUB13586MIG
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
PRIMARY
NCI_THESAURUS
C75938
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
PRIMARY
RXCUI
3416
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID3046322
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
PRIMARY
SMS_ID
100000079199
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
PRIMARY
ECHA (EC/EINECS)
241-493-4
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
PRIMARY
FDA UNII
05D48LUM4Z
Created by admin on Fri Dec 15 15:43:16 UTC 2023 , Edited by admin on Fri Dec 15 15:43:16 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
MAJOR
PLASMA
Related Record Type Details
ACTIVE MOIETY